1. JTO Clin Res Rep. 2020 Jul 1;1(4):100072. doi: 10.1016/j.jtocrr.2020.100072. 
eCollection 2020 Nov.

Leptomeningeal Response to Capmatinib After Progression on Crizotinib in a 
Patient With MET Exon 14-Mutant NSCLC.

Cravero P(1), Vaz N(2), Ricciuti B(1), Clifford SE(1), DiUbaldi G(1), Drevers 
D(1), Morton K(1), Rivenburgh RE(1), Nishino M(2), Awad MM(1).

Author information:
(1)Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute and Harvard 
Medical School, Boston, Massachusetts.
(2)Department of Radiology, Brigham and Women's Hospital and Department of 
Imaging, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 
Massachusetts.

DOI: 10.1016/j.jtocrr.2020.100072
PMCID: PMC8474223
PMID: 34589954